Alpha Tau Medical Ltd. has achieved a significant milestone with the acceptance of its abstract titled “Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This pooled analysis encompasses safety and efficacy data from 58 patients across three prospective clinical studies conducted in Canada and Israel, focusing on the endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

The acceptance of this abstract highlights the growing recognition of Alpha DaRT’s potential within the oncology community, particularly as it pertains to addressing the significant unmet needs in pancreatic cancer treatment. The rigorous peer-review process at ASCO underscores the clinical relevance of the findings, which suggest that the EUS-guided approach is both technically feasible and well-integrated into clinical workflows. The collaboration between gastroenterology, medical oncology, and radiation oncology teams has been pivotal in generating a robust dataset, which is expected to further inform treatment protocols and clinical practices.

The implications of this research extend beyond immediate clinical applications; it signifies a shift in the therapeutic landscape for pancreatic cancer. The ongoing multicenter IMPACT trial in the U.S. and the newly initiated ACAPELLA trial in France are set to evaluate Alpha DaRT in combination with chemotherapy and capecitabine, respectively. This expanding clinical pipeline not only enhances the evidence base for Alpha DaRT but also accelerates the timeline for potential regulatory approvals and market entry, thereby paving the way for innovative treatment options in a field that has historically been resistant to effective therapies.

Source: globenewswire.com